Clinical Trials

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Location:

Rochester,  MN

Trial status:

Open for Enrollment

Why is this study being done?

OBJECTIVES:

- To develop a mechanism for tracking and retaining patients enrolled on COG protocols.

- To maintain regular, lifetime contact with patients in order to obtain current identification and contact information, and self/parent-reported health status.

- To locate patients who are lost-to-follow-up for COG (or Legacy Group) protocols targeted for follow-up by the Long-Term Follow-Up Center (LTFC).

- To provide current patient contact information and self/parent-reported health status updates to the COG Statistics and Data Center (SDC) and to each patient's COG institution.

- To facilitate collection of protocol-specific outcome data through collaboration with the COG Late Effects Committee, the SDC, and the member institutions.

- To collect cumulative therapeutic exposure data (via therapeutic summaries completed online by treating institutions) on patients completing active therapy.

OUTLINE: This is an umbrella protocol for all long-term follow-up at COG institutions. Approximately 6 months after completion of therapy patients receive a mailed packet introducing the Long-Term Follow-Up Center (LTFC) and containing information related to their individualized, protocol-specific follow-up guidelines. Patients are asked to complete a patient response form, verify information provided in packet, update contact information, and complete a Health Status Update Form. The Health Status Update Form is a brief document including questions about current health status, disease status, and cancer therapy received since the last mailing. Patients receive protocol-specific automatic reminders, and may respond by use of postage prepaid envelopes, email, or 24-hour toll-free telephone.

Who is eligible to participate?

DISEASE CHARACTERISTICS:

- Must be newly diagnosed with a primary malignancy and enrolled on a frontline COG therapeutic trial for treatment of a primary malignancy OR must have been enrolled on a COG (or Legacy Group) therapeutic or non-therapeutic trial calling for long-term follow-up, including any of the following:

- Hodgkin lymphoma

- CCG-5942

- POG-9425

- POG-9426

- COG-AHOD0031

- Brain tumor

- CCG-A9961

- Acute lymphoblastic leukemia

- COG-ALTE02C2

- Neuroblastoma

- COG-A3973

- Rhabdomyosarcoma

- IRS-III

- IRS-IV-Stage 1

- IRS-IV-Stage 2/3

- IRS-IV-Stage/Group 4

- Must reside in the U.S. during trial enrollment

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

Last updated: 04/07/2011

NCT ID:

NCT00736749